Delving into the Latest Updates on Nippon Shika Yakuhin Co. Ltd. with Synapse

概览

疾病领域	数量

感染	1

排名前五的药物类型	数量

小分子化药	4

排名前五的靶点	数量

VGSCs(电压门控钠离子通道)	1

关联

4

项与 Nippon Shika Yakuhin Co. Ltd. 相关的药物

Ethyl Aminobenzoate/Tetracaine Hydrochloride/Dibucaine Hydrochloride/Homosulfamine

苯佐卡因/盐酸丁卡因/盐酸辛可卡因/高磺胺

靶点-

作用机制-

在研机构

Nippon Shika Yakuhin Co. Ltd.

原研机构

Nippon Shika Yakuhin Co. Ltd.

在研适应症

麻醉

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期1997-03-14

Tetracycline Hydrochloride/Epidihydrocholesterin

靶点-

作用机制-

在研机构

Nippon Shika Yakuhin Co. Ltd. [+1]

原研机构

Nippon Shika Yakuhin Co. Ltd.

在研适应症

牙周炎 [+4]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期1984-11-06

Mepivacaine Hydrochloride

盐酸甲哌卡因

靶点

VGSCs

作用机制

电压门控钠离子通道阻滞剂

在研机构

Septodont Holding SAS [+4]

原研机构-

在研适应症

麻醉

非在研适应症

臂丛神经病 [+2]

最高研发阶段批准上市

首次获批国家/地区-

首次获批日期1956-01-01

100 项与 Nippon Shika Yakuhin Co. Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Nippon Shika Yakuhin Co. Ltd. 相关的专利（医药）

登录后查看更多信息

4

项与 Nippon Shika Yakuhin Co. Ltd. 相关的文献（医药）

2019-01-02·Journal of Biomaterials Science, Polymer Edition3区 · 工程技术

Preparation of gelatin hydrogel sponges incorporating bioactive glasses capable for the controlled release of fibroblast growth factor-2

3区 · 工程技术

Article

作者: Yokota, Kazuyoshi ; Tabata, Yasuhiko ; Teshima, Hiroki ; Washio, Ayako ; Kitamura, Chiaki

Gelatin hydrogel sponges incorporating bioactive glasses (Gel-BG) were fabricated. We evaluated the characteristics of Gel-BG as scaffolds from the perspective of their mechanical properties and the formation of hydroxyapatite by the incorporation of bioactive glasses (BG). In addition, the Gel-BG degradation and the profile of fibroblast growth factor-2 (FGF-2) release from the Gel-BG were examined. Every Gel-BG showed an interconnected pore structure with the pore size range of 180-200 µm. The compression modulus of sponges incorporating BG increased. The time profiles of degradation for the 72-h crosslinked gelatin hydrogel sponges incorporating 10 wt% BG (Gel-BG(10)) and 50 wt% BG (Gel-BG(50)) were analogous to that of the 24-h crosslinked gelatin hydrogel sponge without BG (Gel-BG(0)). In measuring the release of FGF-2 from Gel-BG, the Gel-BG(10) and Gel-BG(50) showed almost analogous 100% cumulative release within 28 days in vivo. Additionally, a bioactivity evaluation showed that the presence of gelatin does not affect the in vitro bioactivity of Gel-BG. These sponges showed mechanical and chemical functionality as scaffolds, featuring both the controlled release of FGF-2 and the induction of hydroxyapatite crystallization.

2015-01-01·Nihon Shishubyo Gakkai Kaishi (Journal of the Japanese Society of Periodontology)

SPT期におけるテトラサイクリン・エピジヒドロコレステリン含有軟膏の塗布塗擦の有効性評価―予備的検討―

作者: Momose, Manabu ; Murata, Masashi ; Yoshie, Hiromasa ; Kubota, Takehiko ; Tai, Hideaki ; Tomura, Junji

Journal of Japanese Society for Dental Products

Excellent marginal seal and easy removal of a new temporary filling resin, PlastSeal

作者: Tsunekawa, Masayoshi

PlastSeal is an easy-to-use temporary filling resin.Its benefits are: (1) quick filling with simple brush-on-technique right after cavity preparation, and (2) easy removal in one piece with an explorer.Its outstanding benefits differing from conventional temporary filling materials are: (3) excellent sealing ability by administration of the patented Abietic Acid, and (4) elasticity for smooth insertion of an explorer and easy removal without damaging preparation margins even when slight undercuts are present.(1)Microleakage test by Ag⁺ penetration after thermal cycle at 60°C and 4°C, 50 times, showed excellent sealing ability for PlastSeal both at the enamel and the dentin margins, while the other com. available products showed extensive amount of leakage.PlastSeal exhibited the lower resistance in an explorer insertion test and the more elastic property in a shore hardness test than the conventional temporary filling resins.Unpolymerized monomer released from PlastSeal was significantly less than that from an imported temporary filling resin.Exothermic temperature of PlastSeal on polymerization was significantly lower than those of compared products, and the least affects are expected on the living dentin-pulp complex.It is concluded that PlastSeal meets the ideal clin. standards requested for temporary filling, and its excellent clin. performance is expected.

100 项与 Nippon Shika Yakuhin Co. Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Nippon Shika Yakuhin Co. Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

4

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

苯佐卡因/盐酸丁卡因/盐酸辛可卡因/高磺胺	麻醉更多	批准上市
Tetracycline Hydrochloride/Epidihydrocholesterin	口腔炎更多	批准上市
盐酸甲哌卡因 ( VGSCs )	麻醉更多	批准上市
Benzethonium Chloride	消毒剂更多	批准上市